Amylin and Glucagon-Like Peptide-1 (GLP-1): Influence on Gastric Emptying, Appetite and Food Intake in Humans

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

23 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-03-31

Study Completion Date

2008-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this proposal is to dissect the mechanisms controlling gastric emptying, appetite and food intake in humans, and to obtain new knowledge to fight obesity on a pharmacological basis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Oxyntomodulin, Mechanisms of Action in Relation to Appetite, Food Intake, Gastric Emptying and Energy Expenditure.

NCT01232244

Incretin Action Obesity

COMPLETED

Effect of Glucagon-like Peptide 2 on Gallbladder Motility After a Meal in Young, Healthy Male Subjects

NCT03682172

Effect of Glucagon-like Peptide 2 on Gallbladder Motility

COMPLETED EARLY_PHASE1

The Effect of Exogenous Glucagon-like Peptide 2 on Cholecystokinin-induced Gallbladder Emptying

NCT04651868

Gallbladder

COMPLETED NA

The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion

NCT01656057

To Assess the Impact of Bile Acids on Human Glukagon-like-peptide-1 Secretion

COMPLETED NA

The Effect of Liraglutide on the GIT

NCT04008290

Obesity

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of the present study is to elucidate the mechanisms behind the effects of glucagon-like peptide-1 (GLP-1) on gastric emptying, appetite and food intake. The first GLP-1 based anti-diabetic therapy was approved by the FDA in 2005 and is now on the market in the United States. The strong glucose-dependent insulinotropic property of GLP-1 is a highly attractive feature in the pursue of optimal glycaemic control in type 2 diabetes. Moreover, the potential of GLP-1 to reduce gastric emptying, appetite and food intake makes it an attractive tool in the fight against obesity, a pandemic condition that often leads to type 2 diabetes, and several companies are developing weight lowering drugs based on GLP-1. Interestingly, another peptide, amylin, exerts very similar effects on gastric emptying, appetite and food intake in humans. Amylin is found in insulin-rich granules in pancreatic beta-cells and is co-secreted with insulin upon insulinotropic stimuli. Currently, it is not known whether the inhibiting effects of GLP-1 on gastric emptying, appetite and food intake are directly mediated by GLP-1, or if the effects are secondary to the robust insulin responses, and thereby amylin responses, elicited by GLP-1. The objective of the present study is therefore to further elucidate the mechanisms of these effects in order to strengthen the development of anti-diabetic drugs with potential weight lowering capabilities.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with type 1 diabetes

* Informed oral and written consent
* Caucasians over the age of 18 years with type 1 diabetes (diagnosed according to the criteria of WHO) receiving long acting insulin
* C-peptide negative glucagon test
* Normal blood haemoglobin concentration
* Healthy control subjects

* Informed oral and written consent
* Caucasians over the age of 18 years
* Normal 75 g- oral glucose tolerance test (OGTT) according to the criteria of WHO
* Negative islet cell autoantibodies (ICA) and GAD-65 autoantibodies
* No first-degree relatives with diabetes
* Normal blood haemoglobin concentration

Exclusion Criteria

* Patients with type 1 diabetes

* Residual beta-cell function (evaluated with glucagon test)
* Impaired hepatic function (aspartate aminotransferase (ASAT) and/or alanine aminotransferase (ALAT) \> 2 times upper normal limit)
* Diabetic nephropathy (serum-creatinine \> 130 µM and/or albuminuria)
* Diabetic neuropathy
* Proliferative diabetic retinopathy
* Pregnancy, breastfeeding or intention of becoming pregnant or judged to be using inadequate contraceptive measures
* Healthy control subjects

* Impaired hepatic function (ASAT or ALAT \> 2 times upper normal limit)
* Impaired renal function (serum-creatinine \> 130 μM and/or albuminuria)
* First-degree relatives with diabetes
* Pregnancy, breastfeeding or intention of becoming pregnant or judged to be using inadequate contraceptive measures

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes